BTIG analyst Justin Zelin downgraded Kura Oncology stock (NASDAQ:KURA) from Buy to Neutral. Zelin cited concerns over the recent KOMET-001 study results for the company's drug, ziftomenib. The ...
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced its ...
BTIG lowered the firm’s price target on Blue Bird (BLBD) to $45 from $55 and keeps a Buy rating on the shares. The company’s higher than ...
BTIG analyst Gregory Lewis (JO:LEWJ) revised the price target for Blue Bird Corp (NASDAQ:BLBD) shares to $45.00, down from the previous target of $55.00, while reaffirming a Buy rating on the stock.
BTIG analyst Gregory Lewis maintained a Buy rating on Blue Bird (BLBD – Research Report) today and set a price target of $45.00. The company’s ...
BTIG Research lowered shares of IQVIA (NYSE:IQV – Free Report) from a buy rating to a neutral rating in a research report report published on Monday morning, Marketbeat.com reports. Several other ...
Performant Healthcare, Inc. (Nasdaq: PHLT) ("Performant"), a leading provider of technology-enabled payment integrity, eligibility, and related analytics services, announced today that it will ...
This partnership addresses the growing demand among institutional traders for advanced, centralised technology that enables ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback